EODData

MEMBERSHIP REGISTER LOG IN

FRA, 0Z2: Alector Inc

11 Nov 2026
LAST:

2.400

CHANGE:
 0.34		OPEN:
2.210		HIGH:
2.400		ASK:
0.000		VOLUME:
10
CHG(%):
16.73		PREV:
2.056		LOW:
2.210		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 262.2102.4002.2102.40010
10 Nov 262.0562.0562.0562.0560
09 Nov 262.0002.0002.0002.0000
06 Nov 261.9111.9111.9111.9110
05 Nov 261.9851.9851.9851.9850
04 Nov 261.8181.8181.8181.8180
03 Nov 261.8931.8931.8931.8930
02 Nov 261.9331.9331.9331.9330
30 Oct 261.9511.9511.9511.9510
29 Oct 261.9711.9711.9711.9710

PROFILE

Name:Alector Inc
About:Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Address:131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.alector.com
ISIN:US0144421072
LEI:549300Z8RQOIY1JMHC25

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:2.0715.9%
MA10:1.9920.5%
MA20:1.8430.6%
MA50:1.8231.5%
MA100:1.6942.1%
MA200:1.7437.8%
STO9:100.00 
STO14:100.00 
RSI14:75.02 
MTM14:0.78
ROC14:0.48 
ATR:0.10 
Week High:2.400.0%
Week Low:1.8232.0%
Month High:2.400.0%
Month Low:1.6037.8%
Year High:2.400.0%
Year Low:0.96151.3%
Volatility:127.91